Characterisation of behavioural and neurodegenerative changes induced by intranigral 6‐hydroxydopamine lesions in a mouse model of Parkinson’s disease
暂无分享,去创建一个
Anders Björklund | A. Björklund | B. Mattsson | Bengt Mattsson | Shane Grealish | Peter Draxler | S. Grealish | Peter Draxler | Shane Grealish
[1] M. Horne,et al. Fetal striatum- and ventral mesencephalon–derived expanded neurospheres rescue dopaminergic neurons in vitro and the nigro-striatal system in vivo , 2008, Neuroscience.
[2] S. Dunnett,et al. Comparison of 6-hydroxydopamine-induced medial forebrain bundle and nigrostriatal terminal lesions in a lateralised nose-poking task in rats , 2005, Behavioural Brain Research.
[3] Joseph P Huston,et al. Behavioral phenotyping of the MPTP mouse model of Parkinson's disease , 2001, Behavioural Brain Research.
[4] Patrik Brundin,et al. Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice , 2005, Behavioural Brain Research.
[5] U. Ungerstedt,et al. Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. , 1970, Brain research.
[6] H. Lindgren,et al. A model of l-DOPA-induced dyskinesia in 6-hydroxydopamine lesioned mice: relation to motor and cellular parameters of nigrostriatal function , 2004, Neurobiology of Disease.
[7] A. Björklund,et al. Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[8] P. Teitelbaum,et al. Nigrostriatal bundle damage and the lateral hypothalamic syndrome. , 1974, Journal of comparative and physiological psychology.
[9] G. Fisone,et al. Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia , 2005, Experimental Neurology.
[10] A. Hartmann,et al. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and α-synuclein-deleted mice , 2008, Experimental Neurology.
[11] E. Melamed,et al. Intrastriatal transplantation of mouse bone marrow-derived stem cells improves motor behavior in a mouse model of Parkinson's disease. , 2007, Journal of neural transmission. Supplementum.
[12] E. Snyder,et al. Neuroprotection through Delivery of Glial Cell Line-Derived Neurotrophic Factor by Neural Stem Cells in a Mouse Model of Parkinson's Disease , 2001, The Journal of Neuroscience.
[13] M. Tomishima,et al. Therapeutic cloning in individual parkinsonian mice , 2008, Nature Medicine.
[14] O. Lindvall,et al. Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease. , 2009, Trends in pharmacological sciences.
[15] D. Surmeier,et al. Modeling PD pathogenesis in mice: advantages of a chronic MPTP protocol. , 2008, Parkinsonism & related disorders.
[16] H J Gundersen,et al. The efficiency of systematic sampling in stereology and its prediction * , 1987, Journal of microscopy.
[17] Mark J. West,et al. Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias , 1999, Trends in Neurosciences.
[18] O. Lindvall,et al. Wnt5a-treated midbrain neural stem cells improve dopamine cell replacement therapy in parkinsonian mice. , 2008, The Journal of clinical investigation.
[19] K. E. Moore,et al. Turning behavior of mice with unilateral 6-hydroxydopamine lesions in the striatum: effects of apomorphine, L-DOPA, amanthadine, amphetamine and other psychomotor stimulants. , 1973, Neuropharmacology.
[20] A. Björklund,et al. Identification of transplantable dopamine neuron precursors at different stages of midbrain neurogenesis , 2009, Experimental Neurology.
[21] R. Palmiter,et al. Parkin-deficient mice are not more sensitive to 6-hydroxydopamine or methamphetamine neurotoxicity , 2005, BMC Neuroscience.
[22] R. Schwarting,et al. MPTP Susceptibility in the Mouse: Behavioral, Neurochemical, and Histological Analysis of Gender and Strain Differences , 2000, Behavior genetics.
[23] S. Dunnett,et al. Lentivector‐mediated delivery of GDNF protects complex motor functions relevant to human Parkinsonism in a rat lesion model , 2005, The European journal of neuroscience.
[24] Anders Björklund,et al. Characterization of Behavioral and Neurodegenerative Changes Following Partial Lesions of the Nigrostriatal Dopamine System Induced by Intrastriatal 6-Hydroxydopamine in the Rat , 1998, Experimental Neurology.
[25] S. Dunnett,et al. Recovery of functional deficits following early donor age ventral mesencephalic grafts in a rat model of Parkinson's disease , 2008, Neuroscience.
[26] T. Schallert,et al. Intervention Strategies for Degeneration of Dopamine Neurons in Parkinsonism , 2000 .
[27] S. Yamanaka,et al. Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined Factors , 2006, Cell.
[28] U. Ungerstedt,et al. 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. , 1968, European journal of pharmacology.
[29] Stephen B. Dunnett,et al. The Corridor Task: A simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum , 2005, Brain Research Bulletin.
[30] M. Horne,et al. The role of dopamine receptors in regulating the size of axonal arbors. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.